Official Title
An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.
Brief Summary

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.

Unknown status
2019-nCoV

Drug: Abidol hydrochloride

Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.

Drug: Oseltamivir

Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.

Drug: Lopinavir/ritonavir

Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.

Eligibility Criteria

Inclusion Criteria:

1. 2019-nCoV nucleic acid test was positive.

2. CT of the lung conformed to the manifestation of viral pneumonia.

Exclusion Criteria:

1. Patients who meet any of the contraindications in the experimental drug labeling

2. Patients who do not want to participate in this clinical study

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
China
Locations

Department and Institute of Infectious Disease
Wuhan, Hubei, China

Investigator: Qin Ning, professor
qning@vip.sina.com

Contacts

Qing Ning, Professor
+8613971521450
qning@vip.sina.com

Meifang Han, Professor
+8613986093605
mfhan@foxmail.com

Tongji Hospital
NCT Number
MeSH Terms
Pneumonia
Ritonavir
Lopinavir
Oseltamivir